Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Treasury Shares (2016 - 2025)

Avalo Therapeutics' Treasury Shares history spans 8 years, with the latest figure at $387064.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 38.77% year-over-year to $387064.0; the TTM value through Dec 2025 reached $387064.0, down 38.77%, while the annual FY2025 figure was $387064.0, 38.77% down from the prior year.
  • Treasury Shares reached $387064.0 in Q4 2025 per AVTX's latest filing, down from $421397.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $632100.0 in Q3 2024 to a low of $11250.0 in Q4 2021.
  • Average Treasury Shares over 4 years is $295420.0, with a median of $387064.0 recorded in 2025.
  • Peak YoY movement for Treasury Shares: plummeted 92.78% in 2021, then tumbled 33.33% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $11250.0 in 2021, then changed by 0.0% to $11250.0 in 2022, then skyrocketed by 5518.67% to $632100.0 in 2024, then tumbled by 38.77% to $387064.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Treasury Shares are $387064.0 (Q4 2025), $421397.0 (Q3 2025), and $421397.0 (Q2 2025).